Skip to main content
    B

    Biocardia Inc (BCDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.79
    -0.04 (-4.92%)

    Market Cap: $12.58M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biocardia Inc (BCDA) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Biocardia (BCDA) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Biocardia reported EPS of -$0.12, above the -$0.15 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    66%(19/29)
    Avg Surprise
    -12.86%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.16
    Range-$0.21 - -$0.12
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    BCDA has an expected report date of Mar 22, 2027.

    BCDA Earnings Call

    The latest BCDA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, BCDA beat 19, missed 9 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2024, when EPS landed 780.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.12-$0.15-$0.15 - -$0.15+20.00%BeatN/A11 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$0.13-$0.19-$0.19 - -$0.19+31.58%BeatN/A10 up, 1 downAug 12, 2026N/A
    Mar 31, 2026-$0.21-$0.17-$0.17 - -$0.17-23.53%MissN/A10 up, 0 downMay 15, 2026N/A
    Dec 31, 2025-$0.06-$0.20-$0.20 - -$0.20+70.00%BeatN/A11 up, 0 downMar 24, 2026N/A
    Sep 30, 2025-$0.24-$0.25-$0.25 - -$0.25+4.00%BeatN/A10 up, 0 downNov 12, 2025N/A
    Jun 30, 2025-$0.40-$0.50N/A+20.00%BeatN/AN/A0 up, 0 downAug 11, 2025N/A
    Mar 31, 2025-$0.59-$0.39N/A-51.28%MissN/AN/A0 up, 0 downMay 14, 2025N/A
    Dec 31, 2024-$0.25-$0.87-$0.87 - -$0.87+71.26%BeatN/A11 up, 0 downMar 26, 2025N/A
    Sep 30, 2024-$0.61-$1.19N/A+48.74%BeatN/AN/AN/ANov 13, 2024N/A
    Jun 30, 2024-$0.88-$0.10N/A-780.00%MissN/AN/A0 up, 0 downAug 13, 2024N/A
    Mar 31, 2024-$0.09-$0.20N/A+54.90%BeatN/AN/A0 up, 0 downMay 14, 2024$55000
    Dec 31, 2023-$1.35-$1.50-$1.80 - -$1.50+10.00%BeatN/A20 up, 0 downMar 27, 2024$13000
    Sep 30, 2023-$1.80-$1.65-$1.95 - -$1.65-9.09%MissN/A20 up, 0 downNov 8, 2023$357000
    Jun 30, 2023-$2.55-$2.55-$2.55 - -$1.950.00%In lineN/A30 up, 1 downAug 9, 2023$43000
    Mar 31, 2023-$2.55-$1.95-$3.30 - -$1.95-30.77%MissN/A30 up, 0 downMay 10, 2023$64000
    Dec 31, 2022-$0.16-$0.18-$0.22 - -$0.13+11.11%BeatN/A30 up, 0 downMar 29, 2023$106000
    Sep 30, 2022-$2.55-$3.15-$3.75 - -$3.15+19.05%BeatN/A40 up, 0 downNov 9, 2022$212000
    Jun 30, 2022-$2.10-$6.30-$6.30 - -$2.70+66.67%BeatN/A50 up, 0 downAug 10, 2022$974000
    Mar 31, 2022-$2.85-$2.40N/A-18.75%MissN/A30 up, 0 downMay 11, 2022$60000
    Dec 31, 2021-$0.20-$0.21-$0.25 - -$0.12+4.76%BeatN/A40 up, 0 downMar 29, 2022$79000
    Sep 30, 2021-$2.40-$4.20-$4.20 - -$2.85+42.86%BeatN/A40 up, 0 downNov 10, 2021$821000
    Jun 30, 2021-$3.00-$3.45-$3.45 - -$2.70+13.04%BeatN/A3N/AAug 12, 2021$69000
    Mar 31, 2021-$0.18-$0.24-$0.28 - -$0.21+25.00%BeatN/A2N/AMay 13, 2021$46000
    Dec 31, 2020-$3.05-$4.65-$4.65 - -$4.20+34.41%BeatN/A3N/AMar 30, 2021$46000
    Sep 30, 2020-$4.50-$4.35-$4.35 - -$4.05-3.45%MissN/A4N/ANov 10, 2020$34000
    Jun 30, 2020-$6.90-$6.00N/A-15.00%MissN/AN/AN/AAug 13, 2020$27000
    Mar 31, 2020-$7.20-$8.40N/A+14.29%BeatN/A1N/AApr 9, 2020$38000
    Dec 31, 2019-$0.48-$0.51-$0.56 - -$0.46+5.88%BeatN/A2N/ADec 31, 2019$214000
    Sep 30, 2019-$9.45-$8.70N/A-8.62%MissN/AN/AN/ANov 19, 2019$194000
    Jun 30, 2019-$0.77N/AN/AN/AN/AN/AN/AN/AAug 21, 2019$86000
    Mar 31, 2019-$0.85N/AN/AN/AN/AN/AN/AN/AApr 2, 2019$216000
    Dec 31, 2018-$0.85N/AN/AN/AN/AN/AN/AN/AMar 22, 2019$103000
    Sep 30, 2018-$0.81N/AN/AN/AN/AN/AN/AN/ANov 8, 2018$84000
    Jun 30, 2018-$0.72N/AN/AN/AN/AN/AN/AN/AAug 9, 2018$239000
    Mar 31, 2018-$7.59N/AN/AN/AN/AN/AN/AN/AMay 10, 2018$199000
    Dec 31, 2017-$0.81N/AN/AN/AN/AN/AN/AN/AMar 16, 2018$100000
    Sep 30, 2017-$0.72N/AN/AN/AN/A-102.0%N/AN/ANov 9, 2017$130000
    Jun 30, 2017-$10.42N/AN/AN/AN/A-2075.7%N/AN/AAug 14, 2017$112000
    Mar 31, 2017-$10.18N/AN/AN/AN/A-1865.0%N/AN/AMay 11, 2017$137000
    Sep 30, 2016$35.99N/AN/AN/AN/A+6063.0%N/AN/AOct 17, 2016$117000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.29, after -$1.83 the year before. It was $2.27 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.29N/A
    Dec 31, 2024-$1.83N/A
    Dec 31, 2023-$8.25N/A
    Dec 31, 2022-$7.66N/A
    Dec 31, 2021-$5.78N/A
    Dec 31, 2020-$21.65N/A
    Dec 31, 2019-$11.55N/A
    Dec 31, 2018-$9.97-166.7%
    Dec 31, 2017$14.96+560.3%
    Dec 31, 2015$2.27N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,900 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,9425
    2026Q2Jun 30, 20265,5517
    2026Q1Mar 31, 20262,5045
    2025Q4Dec 31, 20253,5426
    2025Q3Sep 30, 20254,0467
    2025Q2Jun 30, 20255,3578
    2025Q1Mar 31, 20253,9827
    2024Q3Sep 30, 20245,0936

    2026Q3 Earnings Call

    Opening remarks

    Miranda Benvenuti Investor Relations Thank you. Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, and references to management's intentions, beliefs, projections, outlook, analyses, and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products and technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia's report on Form 10-K filed with the SEC on March 24, 2026, and in our subsequently filed quarterly reports on Form 10-Q. The content of this call contains time-sensitive information that is accurate only as of today, November 12, 2026. Except as required by law, the company disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Dr. Peter Altman, BioCardia's President and CEO. Peter, please go ahead.

    Peter Altman President and Chief Executive Officer Thank you, Miranda, and good afternoon to everyone on the call. The highlights of this third quarter have been the continued progress on the approval of CardiAMP cell therapy for the treatment of heart failure in Japan and the approval of our Helix transendocardial delivery catheter system in the United States. I would like to focus a little time on each of these regulatory initiatives to detail where we are, the risks, and our anticipated successful outcomes. Our efforts to seek approval in Japan for our CardiAMP cell therapy for the treatment of ischemic heart failure followed Japan's leadership in supporting these therapies, as it has recognized the potential for meaningful impact in treating heart failure. Japan has recently approved and reimbursed a cell therapy for patients with heart failure. Our CardiAMP cell therapy may have advantages over what has been approved in that it is autologous and requires no immunosuppression. Delivering a patient's own cells resonates with Japanese culture, which has historically avoided the transplantation of organs. Further, our CardiAMP cell therapy procedure is performed using minimally invasive catheter delivery, without the need to open the patient's chest surgically to deliver the cells. We expect to be able to discharge patients soon after the procedure, on the same day. The patient need is great, and we look forward to real-world assessment of CardiAMP cell therapy for these patients in Japan.

    Frequently Asked Questions About BCDA

    When is Biocardia's next earnings date?

    Biocardia's next earnings report is expected for Mar 22, 2027.

    Did BCDA beat earnings estimates last quarter?

    Yes. Biocardia reported EPS of -$0.12 for the quarter ended Sep 30, 2026, above the -$0.15 estimate, a 20.00% surprise.

    What EPS do analysts expect from BCDA next quarter?

    The consensus EPS estimate for Biocardia for the quarter ending Dec 31, 2026 is -$0.16 from 4 analysts, with estimates from -$0.21 to -$0.12.

    How often does BCDA beat earnings estimates?

    Biocardia beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +17.75%.